Personalized ventilation for ARDS: early trial halted, results uncertain
NCT ID NCT04012073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether setting a ventilator based on each patient's lung volume could improve outcomes for people with moderate-to-severe acute respiratory distress syndrome (ARDS). The approach used a bedside measurement to tailor the pressure applied during breathing. However, the trial was stopped early after enrolling only 18 participants, so it is not possible to draw firm conclusions about its effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Invasive mechanical ventilation with individualized positive end-expiratory pressure (PEEP) guided by end-expiratory lung volume (EELV) measurement
- What this could lead to
- If successful, this approach could help doctors set ventilators more precisely for each ARDS patient, potentially reducing lung injury and improving survival.
- What could go wrong
- The trial was terminated early with only 18 participants, so results are very limited. It is unclear if the method works better than standard care, and any benefits remain unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
18 people
The number who actually took part.
- Started
-
Nov 2022
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligibility inclusion criteria, according to the ARDS Berlin definition, will be assessed within the first 24 hours from the initiation of invasive mechanical ventilation: 1. Acute respiratory failure within 1 week of a known clinical insult or new or worsening respiratory symptoms; 2. Bilateral infiltrates at the chest x-ray or CT scan, not fully explained by effusions, lobar/lung collapse, or nodules; 3. Respiratory failure not fully explained by cardiac failure or fluid overload; objective assessment required to exclude hydrostatic edema if no risk factor present. 4. PaO2/FiO2 ratio≤150 mmHg after 30 mins - 1 hour of mechanical ventilation with PEEP=5 cmH2O. 5. Written informed consent. Exclusion Criteria: 1. Pregnancy; 2. Pneumothorax; 3. Acute brain injury; 4. Clinical signs of history of decompensated heart failure (New York Heart Association class 3-4 before the acute phase of the disease or documented ejection fraction\<35% or pulmonary capillary wedge pressure\>18 mmHg) or acute coronary syndrome; 5. Intubation as a result of an acute exacerbation of chronic pulmonary disease: chronic obstructive pulmonary disease, asthma, cystic fibrosis, etc; 6. Clinically evident intrinsic PEEP (≥2 cmH2O) during screening visit (End-expiratory pause to achieve Flow=0); 7. BMI\>35; 8. BMI\<15 or body weight\<35 Kg; 9. Any chronic disease requiring long-term oxygen therapy or mechanical ventilation at home; 10. Neuromuscular disease of any kind; 11. Severe chronic liver disease (Child-Pugh C or worse); 12. Bone marrow transplantation or chemotherapy-induced neutropenia; 13. History of liver or lung transplant; 14. Decision to withhold life-sustaining treatment; 15. Need for therapy with inhaled nitric oxide due to documented pulmonary arterial hypertension; 16. Life-threatening hypoxemia deemed to require extracorporeal membrane oxygenation (ECMO); 17. Presence of documented barotrauma; 18. High risk of mortality within 3 months from other than ARDS (severe neurological damage, age \>85 years and cancer patients in terminal stages of the disease). 19. Persistent hemodynamic instability, intractable shock (norepinephrine\>1 mcg/kg/h and/or blood lactate\>5 mmol/L and/or considered too hemodynamically unstable for enrolment in the study by the patient's managing physician). 20. More than 24 hours from endotracheal intubation to the time of the screening visit.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda ospedaliera universitaria di Ferrara-arcispedale Sant'Anna
Ferrara, Italy
-
Azienda ospedaliero-universitaria Mater Domini
Catanzaro, Italy
-
Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
Milan, Italy
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
-
Fondazione Policlinico Universitaro A. Gemelli IRCCS
Rome, Italy
-
Ospedale San Gerardo
Monza, Italy
-
Ospedale San Martino
Genova, Italy
-
Policlinico Sant'Orsola
Bologna, Italy
-
Policlinico di Bari
Bari, Italy
-
SS. Annunziata hospital
Chieti, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donated immune cells calm the cytokine storm?
- Steroid dose showdown: can more dexamethasone save lives in respiratory failure?
- Breathing machine settings put to the test in severe lung injury
- The hidden breath: how a mismatch between patient and machine may shape ARDS recovery
- Scientists hunt for hidden subgroups in sudden respiratory failure
- Bedside ultrasound may reveal hidden diaphragm weakness in older patients struggling to breathe